|
1
|
Wallace MC, Preen D, Jeffrey GP and Adams
LA: The evolving epidemiology of hepatocellular carcinoma: A global
perspective. Expert Rev Gastroenterol Hepatol. 9:765–779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Corvalan AH: Early diagnosis of
hepatocellular carcinoma by microRNAs: Shining a light from the
genome's ‘dark matter’. Dig Dis Sci. 57:2737–2739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Omata M, Cheng A, Kokudo N, Kudo M, Lee
JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al:
Asia-Pacific clinical practice guidelines on the management of
hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang N, Feng J, Li ZR, Ming KH, Lei XX and
Xu BL: Evaluation of serum α-fetoprotein levels during different
infection phases of CHB patients. Clin Lab. 64:43–49. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bai DS, Zhang C, Chen P, Jin SJ and Jiang
GQ: The prognostic correlation of AFP level at diagnosis with
pathological grade, progression, and survival of patients with
hepatocellular carcinoma. Sci Rep. 7:128702017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Daniele B, Bencivenga A, Megna AS and
Tinessa V: Alpha-fetoprotein and ultrasonography screening for
hepatocellular carcinoma. Gastroenterology. 127 (Suppl
1):S108–S112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marks EI and Yee NS: Molecular genetics
and targeted therapy in hepatocellular carcinoma. Curr Cancer Drug
Targets. 16:53–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akhtar B, Muhammad F, Sharif A, Akhtar M
and Majeed W: Diverse signaling pathways and current status of
molecular targeted treatments for hepatocellular carcinoma. Crit
Rev Eukaryot Gene Expr. 27:373–385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh A, Kumar R and Pandey A:
Hepatocellular carcinoma: Causes, mechanism of progression and
biomarkers. Curr Chem Genom Transl Med. 12:9–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klungboonkrong V, Das D and McLennan G:
Molecular mechanisms and targets of therapy for hepatocellular
carcinoma. J Vasc Interv Radiol. 28:949–955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herceg Z and Paliwal A: Epigenetic
mechanisms in hepatocellular carcinoma: How environmental factors
influence the epigenome. Mutat Res. 727:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aigner A: MicroRNAs (miRNAs) in cancer
invasion and metastasis: Therapeutic approaches based on
metastasis-related miRNAs. J Mol Med. 89:445–457. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El-Tawdi AH, Matboli M, Shehata HH, Tash
F, El-Khazragy N, Azazy Ael-S and Abdel-Rahman O: Evaluation of
circulatory RNA-Based biomarker panel in hepatocellular carcinoma.
Mol Diagn Ther. 20:265–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Backes C, Meese E and Keller A: Specific
miRNA disease biomarkers in blood, serum and plasma: Challenges and
prospects. Mol Diagn Ther. 20:509–518. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wurster DH: Sex-chromosome translocations
and karyotypes in bovid tribes. Cytogenetics. 11:197–207. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fendereski M, Zia MF, Shafiee M, Safari F,
Saneie MH and Tavassoli M: MicroRNA-196a as a potential diagnostic
biomarker for esophageal squamous cell carcinoma. Cancer Invest.
35:78–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du C, Zheng J, Lu X and Wang Y:
Downregulation of miR-18a or miR-328 inhibits the invasion and
migration of lung adenocarcinoma A549 cells. Xi Bao Yu Fen Zi Mian
Yi Xue Za Zhi. 32:1051–1054. 2016.(In Chinese). PubMed/NCBI
|
|
20
|
Cheng RF, Wang J, Zhang JY, Sun L, Zhao
YR, Qiu ZQ, Sun BC and Sun Y: MicroRNA-506 is up-regulated in the
development of pancreatic ductal adenocarcinoma and is associated
with attenuated disease progression. Chin J Cancer. 35:642016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun L, Liang J, Wang Q, Li Z, Du Y and Xu
X: MicroRNA-137 suppresses tongue squamous carcinoma cell
proliferation, migration and invasion. Cell Prolif. 49:628–635.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan X, Wang ZX and Wang R: MicroRNA-21: A
novel therapeutic target in human cancer. Cancer Biol Ther.
10:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo X, Lv X, Lv X, Ma Y, Chen L and Chen
Y: Circulating miR-21 serves as a serum biomarker for
hepatocellular carcinoma and correlated with distant metastasis.
Oncotarget. 8:44050–44058. 2017.PubMed/NCBI
|
|
25
|
Eteriia GP: Characteristics of suture
materials for bronchoplasty. Vestn Khir Im I I Grek. 107:103–108.
1971.(In Russian). PubMed/NCBI
|
|
26
|
Wang X, Zhang J, Zhou L, Lu P, Zheng ZG,
Sun W, Wang JL, Yang XS, Li XL, Xia N, et al: Significance of serum
microRNA-21 in diagnosis of hepatocellular carcinoma (HCC):
Clinical analyses of patients and an HCC rat model. Int J Clin Exp
Pathol. 8:1466–1478. 2015.PubMed/NCBI
|
|
27
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zamora J, Abraira V, Muriel A, Khan K and
Coomarasamy A: Meta-DiSc: A software for meta-analysis of test
accuracy data. BMC Med Res Methodol. 6:312006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jackson D, White IR and Thompson SG:
Extending DerSimonian and Laird's methodology to perform
multivariate random effects meta-analyses. Stat Med. 29:1282–1297.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deeks JJ, Macaskill P and Irwig L: The
performance of tests of publication bias and other sample size
effects in systematic reviews of diagnostic test accuracy was
assessed. J Clin Epidemiol. 58:882–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T,
Huang L, Li H, Tan W, Wang C and Lin D: Circulating microRNAs,
miR-21, miR-122, and miR-223, in patients with hepatocellular
carcinoma or chronic hepatitis. Mol Carcinog. 50:136–142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu AM, Yao TJ, Wang W, Wong KF, Lee NP,
Fan ST, Poon RT, Gao C and Luk JM: Circulating miR-15b and miR-130b
in serum as potential markers for detecting hepatocellular
carcinoma: A retrospective cohort study. BMJ Open. 2:e0008252012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Amr K, Ezzat W, Elhosary Y, Hegazy A,
Fahim H and Kamel R: The potential role of miRNAs 21 and 199-a in
early diagnosis of hepatocellular carcinoma. Gene. 575:66–70. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhuang C, Jiang W, Huang D, Xu L, Yang Q,
Zheng L, Wang X and Hu L: Serum miR-21, miR-26a and miR-101 as
potential biomarkers of hepatocellular carcinoma. Clin Res Hepatol
Gastroenterol. 40:386–396. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tomimaru Y, Eguchi H, Nagano H, Wada H,
Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I,
Umeshita K, et al: Circulating microRNA-21 as a novel biomarker for
hepatocellular carcinoma. J Hepatol. 56:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mizuguchi Y, Mishima T, Yokomuro S, Arima
Y, Kawahigashi Y, Shigehara K, Kanda T, Yoshida H, Uchida E, Tajiri
T and Takizawa T: Sequencing and bioinformatics-based analyses of
the microRNA transcriptome in hepatitis B-related hepatocellular
carcinoma. PLoS ONE. 6:e153042011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qin Z, Zhu X and Huang Y: Circulating
microRNA-21 as a novel biomarker for hepatocellular carcinoma.
Sichuan Med J. 34:1463–1465. 2013.
|
|
40
|
Burchard J, Zhang C, Liu AM, Poon RT, Lee
NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al:
microRNA-122 as a regulator of mitochondrial metabolic gene network
in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li W, Xie L, He X, Li J, Tu K, Wei L, Wu
J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic
implications of microRNAs in human hepatocellular carcinoma. Int J
Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Murakami Y, Kubo S, Tamori A, Itami S,
Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH:
Comprehensive analysis of transcriptome and metabolome analysis in
intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Sci
Rep. 5:162942015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao L and Zhang Y: miR-342-3p affects
hepatocellular carcinoma cell proliferation via regulating
NF-kappaB pathway. Biochem Biophys Res Commun. 457:370–377. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shen J, Wang A, Wang Q, Gurvich I, Siegel
AB, Remotti H and Santella RM: Exploration of genome-wide
circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a
potential biomarker. Cancer Epidemiol Biomarkers Prev.
22:2364–2373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Clancy C, Joyce MR and Kerin MJ: The use
of circulating microRNAs as diagnostic biomarkers in colorectal
cancer. Cancer Biomark. 15:103–113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Labib H, Elantouny N, Ibrahim N and
Alnagar A: Upregulation of microRNA-21 is a poor prognostic marker
in patients with childhood B cell acute lymphoblastic leukemia.
Hematology. 22:392–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu Y, Song Y, Xiong Y, Wang X, Xu K, Han
B, Bai Y, Li L, Zhang Y and Zhou L: MicroRNA-21 (Mir-21) promotes
cell growth and invasion by repressing tumor suppressor PTEN in
colorectal cancer. Cell Physiol Biochem. 43:945–958. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zeng Z, Wang J, Zhao L, Hu P, Zhang H,
Tang X, He D, Tang S and Zeng Z: Potential role of microRNA-21 in
the diagnosis of gastric cancer: A meta-analysis. PLoS One.
8:e732782013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qu K, Zhang X, Lin T, Liu T, Wang Z, Liu
S, Zhou L, Wei J, Chang H, Li K, et al: Circulating miRNA-21-5p as
a diagnostic biomarker for pancreatic cancer: Evidence from
comprehensive miRNA expression profiling analysis and clinical
validation. Sci Rep. 7:16922017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Feng YH and Tsao CJ: Emerging role of
microRNA-21 in cancer. Biomed Rep. 5:395–402. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen
CL, Su J, Wang LY, Lu SN, You SL, Chen DS, et al: Associations
between hepatitis B virus genotype and mutants and the risk of
hepatocellular carcinoma. J Natl Cancer Inst. 100:1134–1143. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xie Y: Hepatitis B virus-associated
hepatocellular carcinoma. Adv Exp Med Biol. 1018:11–21. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Xie K, Zhang Y, Liu J, Zeng Y and Wu H:
MicroRNAs associated with HBV infection and HBV-related HCC.
Theranostics. 4:1176–1192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Song W, Wang L, Wang L and Li Q: Interplay
of miR-21 and FoxO1 modulates growth of pancreatic ductal
adenocarcinoma. Tumour Biol. 36:4741–4745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lei BX, Liu ZH, Li ZJ, Li C and Deng YF:
miR-21 induces cell proliferation and suppresses the
chemosensitivity in glioblastoma cells via downregulation of FOXO1.
Int J Clin Exp Med. 7:2060–2066. 2014.PubMed/NCBI
|
|
60
|
Go H, Jang JY, Kim PJ, Kim YG, Nam SJ,
Paik JH, Kim TM, Heo DS, Kim CW and Jeon YK: MicroRNA-21 plays an
oncogenic role by targeting FOXO1 and activating the PI3K/AKT
pathway in diffuse large B-cell lymphoma. Oncotarget.
6:15035–15049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dong T, Zhang Y, Chen Y, Liu P, An T,
Zhang J, Yang H, Zhu W and Yang X: FOXO1 inhibits the invasion and
metastasis of hepatocellular carcinoma by reversing ZEB2-induced
epithelial-mesenchymal transition. Oncotarget. 8:1703–1713.
2017.PubMed/NCBI
|
|
62
|
Sun H, Hou J, Shi W and Zhang L: Estrogen
receptor 1 (ESR1) genetic variations in cancer risk: A systematic
review and meta-analysis. Clin Res Hepatol Gastroenterol.
39:127–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Breyer J, Wirtz R, Laible M, Schlombs K,
Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, et
al: ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade
of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch.
469:547–552. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dou CY, Fan YC, Cao CJ, Yang Y and Wang K:
Sera DNA methylation of CDH1, DNMT3b and ESR1 promoters as
biomarker for the early diagnosis of hepatitis B virus-related
hepatocellular carcinoma. Dig Dis Sci. 61:1130–1138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hishida M, Nomoto S, Inokawa Y, Hayashi M,
Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S,
et al: Estrogen receptor 1 gene as a tumor suppressor gene in
hepatocellular carcinoma detected by triple-combination array
analysis. Int J Oncol. 43:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Weng TY, Wang CY, Hung YH, Chen WC, Chen
YL and Lai MD: Differential expression pattern of THBS1 and THBS2
in lung cancer: Clinical outcome and a systematic-analysis of
microarray databases. PLoS One. 11:e01610072016. View Article : Google Scholar : PubMed/NCBI
|
